Holen Sie sich die Stockscreener-App
16.51
5.97%
0.93
Handel nachbörslich:
16.50
-0.01
-0.06%
Schlusskurs vom Vortag:
$15.58
Offen:
$16
24-Stunden-Volumen:
872.12K
Relative Volume:
1.05
Marktkapitalisierung:
$1.79B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-11.79
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
+0.30%
1M Leistung:
-14.59%
6M Leistung:
+2.23%
1J Leistung:
+39.56%
1-Tages-Spanne:
$16.00
$16.60
1-Wochen-Bereich:
$15.25
$16.60
52-Wochen-Spanne:
$11.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
16.51 | 1.79B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Novocure (NVCR) Gains CE Mark for Optune Lua in Lung Cancer Treatment | NVCR Stock News - GuruFocus
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer | NVCR Stock News - GuruFocus
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer - Yahoo Finance
LPL Financial LLC Acquires Shares of 27,861 NovoCure Limited (NASDAQ:NVCR) - Defense World
Wedbush Issues Pessimistic Forecast for NovoCure Earnings - Defense World
NovoCure (NASDAQ:NVCR) vs. Sonoma Pharmaceuticals (NASDAQ:SNOA) Financial Review - Defense World
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Why NovoCure Stock Was Withering on Wednesday - MSN
NovoCure (NASDAQ:NVCR) Upgraded to “Hold” at StockNews.com - Defense World
Why NovoCure (NVCR) Stock Fell Today - GuruFocus
Novocure price target lowered to $27 from $29 at Wedbush - TipRanks
Wedbush Adjusts Price Target for Novocure (NVCR) Ahead of Earnings Report | NVCR Stock News - GuruFocus
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for NovoCure (NASDAQ:NVCR) Stock Price - Defense World
11,672 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Raymond James Financial Inc. - Defense World
NovoCure Escapes Investor Suit Over Cancer Therapy Trial Data - Bloomberg Law News
NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com - Defense World
NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week - simplywall.st
Thrivent Financial for Lutherans Reduces Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Corebridge Financial Inc. Has $1.58 Million Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure to Report First Quarter 2025 Financial Results - Yahoo Finance
Emerald Advisers LLC Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Proficio Capital Partners LLC Acquires Shares of 30,158 NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
NovoCure Beats Investor Lawsuit Over Cancer Trial Data Results - Bloomberg Law News
Charles Schwab Investment Management Inc. Has $24.92 Million Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Beats Investor Suit Over Cancer Therapy Trial Data (1) - Bloomberg Law News
NovoCure (NASDAQ:NVCR) Rating Increased to Hold at StockNews.com - Defense World
Bank of New York Mellon Corp Increases Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily
Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields By Investing.com - Investing.com India
Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields - Investing.com
Principal Financial Group Inc. Invests $272,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure Ltd. to Host Earnings Call - ACCESS Newswire
Truist Financial Corp Invests $340,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World
Don't Ignore The Insider Selling In NovoCure - Simply Wall St
Novocure’s EVP sells shares worth $46,841 By Investing.com - Investing.com Australia
Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus.com
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - MSN
Novocure’s chief innovation officer sells shares worth $5,071 - Investing.com India
Novocure’s EVP sells shares worth $46,841 - Investing.com India
Novocure CEO Ashley Cordova sells shares valued at $38,055 By Investing.com - Investing.com South Africa
Novocure CEO Ashley Cordova sells shares valued at $38,055 - Investing.com
Novocure COO sells shares worth $4,634 By Investing.com - Investing.com Australia
Novocure COO sells shares worth $4,634 - Investing.com
Novocure’s COO Paravasthu Mukund sells shares worth $39,687 By Investing.com - Investing.com Australia
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference - Yahoo Finance
NovoCure (NASDAQ:NVCR) Lowered to “Sell” Rating by StockNews.com - Defense World
NovoCure Executives Cash In: Major Stock Sales Unveiled! - TipRanks
Insider Sell: Uri Weinberg Sells Shares of NovoCure Ltd (NVCR) - GuruFocus.com
NovoCure’s Earnings Call: Growth Amid Challenges - MSN
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):